Dr. Tuite is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
909 Fulton St SE
Minneapolis, MN 55455
Summary
- Board certified Neurologist with expertise in movement disorders; working at the University of Minnesota/UM Physicians. Focused on Parkinson's disease and other movement disorders
Education & Training
- University of Toronton/a, Movement Fellowship and Neurophysiology, n/a, 1994 - 1996
- McGill University Fellowship, 1993 - 1994
- McGill University Residency, 1991 - 1993
- Indiana University School of MedicineResidency, Neurology, 1990 - 1991
- Indiana University School of Medicine/Methodist HospitalInternship, Transitional Year, 1989 - 1990
- Indiana University School of MedicineClass of 1989
- Northwestern UniversityBA, Chemistry, 1981 - 1985
Certifications & Licensure
- MN State Medical License 1996 - 2025
- WI State Medical License 2021 - 2025
- ND State Medical License 2021 - 2022
- American Board of Psychiatry and Neurology Neurology
- national board of neurology and psychiatryneurology
Awards, Honors, & Recognition
- Clinical Scholar/research University of Minnesota Medical Center, 2012
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Top Doctor 2012-2014
- Join now to see all
Clinical Trials
- 7T MRS in Parkinson's Disease Start of enrollment: 2010 Feb 01
- Detecting Dopaminergic Deficits in Individuals At-risk for Parkinsonism Start of enrollment: 2011 Jul 01
- Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease Start of enrollment: 2011 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 14 citationsGBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologiesParker H. Johnson, Neal J. Weinreb, James C. Cloyd, Paul J. Tuite, Reena V. Kartha
Molecular Genetics and Metabolism. 2020-02-01 - 90 citationsLong-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.Robert A. Hauser, Mark F. Lew, Howard I. Hurtig, William G. Ondo, Joanne Wojcieszek
Movement Disorders. 2009-03-15 - 48 citationsRasagiline improves quality of life in patients with early Parkinson's diseaseKevin M. Biglan, Steven R. Schwid, Shirley Eberly, Karen Blindauer, S. Fahn
Movement Disorders. 2006-05-01
Journal Articles
- Impulsive behavior and associated clinical variables in Parkinson’s disease.Abosch A, Gupte A, Eberly LE, Tuite PJ, Nance M, Grant JE, Psychosomatics
- A recommended scale for cognitive screening in clinical trials of Parkinson’s disease.Chou KL, Amick MM, Brandt J, Camicioli R, Frei K, Gitelman D, Goldman J, Hurtig HI, Levin B, Litvan I, Marsh L, Simuni T, Troster AI, Uc EY, Mov Disord 25:2501-7
- Cancer incidence in a trial of an antiapoptotic agent for Parkinson’s disease.Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE, Shoulson I; PSG PRECEPT Investigators (Tuite P; UM Site Investigator), Hyson C, Oakes D, Flagg..., Mov Disord 25:1801-8, 1992-8
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Abstract on MR spectroscopy.Grüetter R, Tuite P, Twelfth Scientific Meeting of ISMRM, Kyoto, Japan
- Ugurbil. Assessment of brain iron and a neuronal marker in patients with Parkinson’s disease using novel MRI contrasts.Tuite, P, Michaeli S, Sorce D, Oz G, Garwood M, Mov Disord 21(S15): S454
- Assessment of Brain Iron and a Neuronal Marker in Patients with Parkinson’s disease Using Novel MRI Contrasts.Michaeli S, Sorce D, Oz G, Ugurbil K, Garwood M, Tuite, P, Mov Disord 21(9):1545
- Join now to see all
Lectures
- Movement Disorders for healthcare professionals.The Geritom Education Center
- Pathophysiology of Parkinson's disease: How it Relates to Swallowing Function and Medical Treatment.Seventh Annual Dysphagia Research Society Meeting, New Orleans, Louisiana
- Drug Treatment for the Management of Parkinson’s Disease: Dopamine Agonist.The First Annual Update in Movement Disorders and General Neurology at the Cleveland Clinic, Florida
- Join now to see all
Other
- Parkinson’s disease program multiple talks and panel discussion.Paul Joseph Tuite
http://mnpdforum.roundtablelive.org/ - 30 minute TPT.Paul Joseph Tuite, Channel 2 public TV
TV program on Parkinson’s disease
Press Mentions
- UMN Researchers Begin Three COVID-19 Trials, Test Malaria DrugMarch 18th, 2020
- Minnesota Man Among the First in the Country to Receive Next Generation DBS Device for Parkinson’s DiseaseMarch 27th, 2024
Grant Support
- Assessment Of Brain Iron In Parkinson'S Disease By T2p And T1p MRINational Center For Research Resources2008
- 4 Tesla Magnetic Resonance Spectroscopy In Parkinson'S DiseaseNational Center For Research Resources2005–2007
- Parkinson'S Disease: Cognition, Executive Function, And Personally-Relevant DeciNational Center For Research Resources2005–2006
- FMRI Finger Tapping Study In Parkinson'S DiseaseNational Center For Research Resources2004–2005
- Magnetic Resonance Spectroscopy (MRS) For Neurological ConditionsNational Center For Research Resources2004
- GDNF For Treatment Of Patients W/ Idiopathic Parkinsons DiseaseNational Center For Research Resources2000
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: